Furthermore, genetic heterogeneity of AML, such as upregulation of BCL2A1 and CLEC7A or mutations of PTPN11 and KRAS, confers resistance to VEN, which has not been considered (Zhang et al. 2020). The gene discussed is BCL2A1; the disease is acute myeloid leukemia.